Morin exerts neuroprotective actions in Parkinson disease models in vitro and in vivo

Acta Pharmacologica Sinica

Volumn 31, Issue 8, 2010, Pages 900-906

  Zhang, Zhen Tao ^a,b   Cao, Xue Bing ^b   Xiong, Nian ^b   Wang, Hong Cai ^b   Huang, Jin Sha ^b   Sun, Sheng Gang ^b   Wang, Tao ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

apoptosis; dopamine; morin; MPTP; Parkinson disease; PC12 cells

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CASPASE 3; DOPAMINE; MORIN; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN DAMAGE; CELL ASSAY; CELL LOSS; CELL STRAIN; CELL VIABILITY; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; MOTOR DYSFUNCTION; NERVE CELL CULTURE; NERVE CELL DIFFERENTIATION; NERVE CELL NECROSIS; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; PARKINSON DISEASE; RAT; TREATMENT RESPONSE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIPARKINSON AGENTS; APOPTOSIS; CELL SURVIVAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; FLOW CYTOMETRY; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; PARKINSONIAN DISORDERS; PC12 CELLS; RATS; REACTIVE OXYGEN SPECIES;

EID: 77955456603     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.77     Document Type: Article

References (35)

1. Lang AE. The progression of Parkinson disease: a hypothesis. Neurology 2007; 68: 948-952
2. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591-596
3. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008; 7: 97-109.
4. Schulz JB. Update on the pathogenesis of Parkinson's disease. Neurol 2008; 255 Suppl 5: 3-7.
5. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009; 40: e331-9.
6. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
7. Aquilano K, Baldelli S, Rotilio G, Ciriolo MR. Role of nitric oxide synthases in Parkinson's disease: a review on the antioxidant and anti-infammatory activity of polyphenols. Neurochem Res 2008; 33: 2416-2426
8. Guo S, Bezard E, Zhao B. Protective effect of green tea polyphenols on the SH-SY5Y cells against 6-OHDA induced apoptosis through ROS-NO pathway. Free Radic Biol Med 2005; 39: 682-695
9. Pan T, Jankovic J, Le W. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging 2003; 20: 711-721
10. Reznichenko L, Amit T, Zheng H, Avramovich-Tirosh Y, Youdim MB, Weinreb O, et al. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 2006; 97: 527-536
11. Gottlieb M, Leal-Campanario R, Campos-Esparza MR, Sánchez- Gómez MV, Alberdi E, Arranz A, et al. Neuroprotection by two polyphenols following excitotoxicity and experimental ischemia. Neurobiol Dis 2006; 23: 374-386
12. Ibarretxe G, Sánchez-Gómez MV, Campos-Esparza MR, Alberdi E, Matute C. Differential oxidative stress in oligodendrocytes and neurons after excitotoxic insults and protection by natural polyphenols. Glia 2006; 53: 201-211
13. Wu TW, Fung KP, Zeng LH, Wu J, Hempel A, Grey AA, et al. Molecular properties and myocardial salvage effects of morin hydrate. Biochem Pharmacol 1995; 49: 537-543
14. Campos-Esparza MR, Sánchez-Gómez MV, Matute C. Molecular mechanisms of neuroprotection by two natural antioxidant poly-phenols. Cell Calcium 2009; 45: 358-368
15. Mazzio E, Huber J, Darling S, Harris N, Soliman KF. Effect of anti-oxidants on L-glutamate and N-methyl-4-phenylpyridinium ion induced-neurotoxicity in PC12 cells. Neurotoxicology 2001; 22: 283-288
16. Jackson-Lewis V, Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2007; 2: 141-151
17. Sanberg PR, Bunsey MD, Giordano M, Norman AB. The catalepsy test: its ups and downs. Behav Neurosci 1988; 102: 748-759
18. Viaro R, Sanchez-Pernaute R, Marti M, Trapella C, Isacson O, Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiol Dis 2008; 30: 430-438
19. Geng X, Tian X, Tu P, Pu X. Neuroprotective effects of echinacoside in the mouse MPTP model of Parkinson's disease. Eur J Pharmacol 2007; 564: 66-74.
20. Lipman T, Tabakman R, Lazarovici P. Neuroprotective effects of the stable nitroxide compound Tempol on 1-methyl-4-phenylpyridinium ion-induced neurotoxicity in the Nerve Growth Factor-differentiated model of pheochromocytoma PC12 cells. Eur J Pharmacol 2006; 549: 50-57.
21. Soldner F, Weller M, Haid S, Beinroth S, Miller SW, Wüllner U, et al. MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/ Cip1). Exp Cell Res 1999; 250: 75-85.
22. Chung WG, Miranda CL, Maier CS. Epigallocatechin gallate (EGCG) potentiates the cytotoxicity of rotenone in neuroblastoma SH-SY5Y cells. Brain Res 2007; 1176: 133-142
23. Kinen TM, Piltonen M, Ossola B, Kekki H, Lehtonen S, Nenonen T, et al. Lack of robust protective effect of quercetin in two types of 6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell cultures. Brain Res 2008; 1203: 149-159
24. Zeng LH, Wu J, Fung B, Tong JH, Mickle D, Wu TW. Comparative protection against oxyradicals by three flavonoids on cultured endothelial cells. Biochem Cell Biol 1997; 75: 717-720
25. Chetsawang B, Kooncumchoo P, Govitrapong P, Ebadi M. 1-Methyl-4-phenyl- pyridinium ion-induced oxidative stress, c-Jun phosphorylation and DNA fragmentation factor-45 cleavage in SK-N-SH cells are averted by selegiline. Neurochem Int 2008; 53: 283-288
26. Joglar B, Rodriguez-Pallares J, Rodriguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The infammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 2009; 109: 656-669
27. Marella M, Seo BB, Matsuno-Yagi A, Yagi T. Mechanism of cell death caused by complex I defects in a rat dopaminergic cell line. J Biol Chem 2007; 282: 24146-24156
28. Zhang R, Kang KA, Piao MJ, Maeng YH, Lee KH, Chang WY, et al. Cellular protection of morin against the oxidative stress induced by hydrogen peroxide. Chem Biol Interact 2009; 177: 21-27
29. Manna SK, Aggarwal RS, Sethi G, Aggarwal BB, Ramesh GT. Morin (3,5,7,2',4'-Pentahydroxyflavone) abolishes nuclear factor-kappaB activation induced by various carcinogens and infammatory stimuli, leading to suppression of nuclear factor-kappaB-regulated gene expres sion and up-regulation of apoptosis. Clin Cancer Res 2007; 13: 2290-2297
30. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, Hartley DM, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 2007; 104: 18754-18759
31. Kempuraj D, Madhappan B, Christodoulou S, Boucher W, Cao J, Papadopoulou N, et al. Flavonols inhibit proinflammatory mediator release, intracellular calcium ion levels and protein kinase C theta phos phoryla tion in human mast cells. Br J Pharmacol 2005; 145: 934-944
32. Abd El Mohsen MM, Kuhnle G, Rechner AR, Schroeter H, Rose S, Jenner P, et al. Uptake and metabolism of epicatechin and its access to the brain after oral ingestion. Free Radic Biol Med 2002; 33: 1693-1702
33. Youdim KA, Qaiser MZ, Begley DJ, Rice-Evans CA, Abbott NJ. Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radic Biol Med 2004; 36: 592-604.
34. Cho YM, Onodera H, Ueda M, Imai T, Hirose M. A 13-week subchronic toxicity study of dietary administered morin in F344 rats. Food Chem Toxicol 2006; 44: 891-897
35. Rotelli AE, Guardia T, Juárez AO, de la Rocha NE, Pelzer LE. Comparative study of flavonoids in experimental models of inflamma tion. Pharmacol Res 2003; 48: 601-606